Table 3.
BEP | (repeat cycles every 3 weeks)a | reference [97] | |
Cisplatin | 20 mg/m2 | Day 1–5 | |
Etoposide | 100 mg/m2 | Day 1–5 | |
Bleomycin | 30 mg | Day 1, 8, 15 | |
EP | (repeat cycles every 3 weeks)b | reference [33] | |
Cisplatin | 20 mg/m2 | Day 1–5 | |
Etoposide | 100 mg/m2 | Day 1–5 | |
VIP | (repeat cycles every 3 weeks)c | reference [98] | |
Cisplatin | 20 mg/m2 | Day 1–5 | |
Etoposide | 75 mg/m2 | Day 1–5 | |
Ifosfamide | 1,2 g | Day 1–5 |
aThree cycles BEP in IGCCCG ‘good prognosis’ patients; four cycles BEP in IGCCCG ‘intermediate prognosis’ and ‘poor prognosis’ patients.
bFour cycles EP only in IGCCCG ‘good prognosis’ patients with contraindications to bleomycin.
cFour cycles VIP only in IGCCCG ‘intermediate risk‘ and ‘poor risk’ patients with contraindications to bleomycin.
VIP, cisplatin, etoposide and ifosfamide.